Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Alteryx

Salesforce

Datadog

MongoDB

Snowflake

Splunk

Data stocks often fly under the radar. However, investors should keep these names in mind as they power tech innovations forward.

7 Data-Driven Stocks for a Wave of Innovation 

The medical genetics company easily topped Wall Street's top- and bottom-line estimates in the third quarter.

What's Behind Invitae's Q3 Earnings Beat

Invitae Corporation. (NVTA) CEO Sean George on Q3 2020 Results - Earnings Call Transcript

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.

Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?

SAN FRANCISCO, Oct. 23, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m....

Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Invitae (NVTA) Stock?

SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that...

Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide

Becton, Dickinson and Co.

Exact Sciences

Guardant Health Inc

Illumina

Natera

QuidelOrtho Corp

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

7 Diagnostic and Genomic Stocks Storming Into October

Which stock wins in this genetics version of David versus Goliath?

Better Buy: Invitae vs. Illumina

SAN FRANCISCO, Sept. 11, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, effective September 10, 2020.

Invitae Appoints Kimber Lockhart to its Board of Directors

The company is rapidly expanding its business in order to cement a strong foothold in the fast-growing genetics market.

Invitae: Revolutionizing Genetic Testing

CRISPR Therapeutics

Here's how a sector fund can help you find top stocks in sizzling sectors. They’re a great place to start, especially when you want to gain exposure to a specific hypergrowth trend.

How to Find the Top Stocks in the Hottest Sectors

SAN FRANCISCO, Sept. 3, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to.

Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer

SAN FRANCISCO, Sept. 1, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Monday,.

Invitae to Participate in the Morgan Stanley Virtual Global Healthcare Conference

Novavax

SPDR S&P Biotech ETF

Nearby support levels and well-defined risk/reward setups will likely make the biotech sector a favorite of active traders for the rest of 2020.

3 Charts Suggest Biotech Stocks Are Headed Higher

SAN FRANCISCO--(BUSINESS WIRE)---- $NVTA #VC--Civilization Ventures is announcing the close of its second fund following the successful investment of Fund I in 2017, where the firm had major portfolio exits with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and the acquisition of Singular Bio by Invitae, Inc. (NYSE: NVTA), a publicly traded company at the forefront of advanced medical genetics.

Civilization Ventures Announces $35M Second Fund

Not all of the genetic tests it sells were particularly in demand as the COVID-19 pandemic intensified.

Invitae Posts a Loss After a Revenue Decline in the Second Quarter

Invitae Corporation's (NVTA) CEO Sean George on Q2 2020 Results - Earnings Call Transcript

SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D.

Invitae Reports Inducement Grants Under NYSE Rule 303A.08

SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2020.

Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Invitae (NVTA) to Report a Decline in Earnings: What to Look Out for

Genetic testing is likely to drive Invitae's (NVTA) Q2 earnings.

Invitae (NVTA) to Report Q2 Earnings: What's in the Cards?

SAN FRANCISCO, July 21, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m.

Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020

GenMark Diagnostics

Mike Cintolo is a leading growth stock expert and is the editor of Cabot Top Ten Trader.

2 Companies In The Fast-Growing Market For Molecular Diagnostics And Genetic Testing

Does Invitae (NVTA) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for Invitae Stock (NVTA)